Volpara Health Hits Remarkable Milestone in AI Research
This accomplishment emphasizes advancements in AI for breast cancer detection.
Volpara Health, a leader in artificial intelligence (AI)-powered breast health solutions, has made a significant leap forward with the publication of its 300th peer-reviewed scientific paper. This pivotal achievement highlights Volpara's unwavering dedication to improving breast cancer detection and personalizing patient care through the application of evidence-based AI technologies.
The Importance of Peer-Reviewed Validation
The clinical adoption of mammography AI technologies heavily relies on the existence of robust, peer-reviewed validation. A comprehensive review examining 100 CE-marked AI products in radiology uncovered that a staggering 64% of these products did not provide peer-reviewed evidence of their efficacy. In stark contrast, Volpara Health stands tall within the industry, boasting the highest number of peer-reviewed scientific publications, validating its innovative approaches for quality assurance.
Trust Earned Through Rigor and Innovation
Teri Thomas, CEO of Volpara Health and CBO of Lunit, stated, "Our milestone of 300 studies illustrates the deep trust our technology has generated within academic and clinical communities. Our commitment to peer validation is paramount, providing critical evidence that our AI solutions assist in achieving measurable improvements in breast cancer detection and patient outcomes."
Latest Studies Showcasing Volpara’s AI Capabilities
Recent studies that illustrate its AI technology effectiveness encompass various angles of patient screening and mammography efficiency.
Enhancing Radiologist Performance
The study titled, **Breast Density-Based Mammogram Ordering Enhances Interpretation** reveals how the strategic ordering of mammograms based on breast density can substantially enhance radiologists' reading performance. By arranging mammograms in ascending order of volumetric breast density (VBD), reading time decreased while specificity increased from 86% to 89%, thereby escalating the accuracy of cancer detection. Dr. Lars Grimm, who commented on the findings, mentioned that the deliberate ordering could seamlessly fit into existing batch-reading workflows.
Identification of At-Risk Women
Another significant study, **Breast Density Effect on the Sensitivity of Digital Screening Mammography in a UK Cohort**, employed Volpara's AI algorithms to analyze how breast density impacts cancer detection rates. The research affirmed that Volpara’s technology is capable of effectively identifying women who are at a heightened risk of missed cancers during mammography, thus underscoring the necessity for personalized screening protocols.
The Ongoing Commitment to Research and Development
Melissa Hill, PhD, Senior Imaging Scientist and Global Research Lead at Volpara Health, highlighted the essence of scientific integrity, saying, "Our research partnerships and relentless pursuit of innovation are crucial in reaching this milestone. Every published paper undergoing rigorous evaluation bolsters the confidence clinicians place in our solutions to elevate patient care outcomes."
Volpara's journey from its initial publication to the current milestone of 300 peer-reviewed papers spans over 15 years, characterized by continuous innovation and dedicated investment in research. The company remains focused on its mission to advance AI technologies aimed at enhancing breast health for all.
About Volpara Health
Volpara Health is driven by its mission to protect families from cancer through AI-infused software that enables healthcare providers to better evaluate cancer risks and navigate tailored care decisions. With its solutions deployed across over 3,500 facilities and serving more than 5,600 technologists worldwide, Volpara impacts nearly 18 million patients annually. Moreover, it facilitates around 3.6 million cancer risk assessments each year. Volpara seamlessly integrates with electronic health records and imaging systems, providing radiologists the ability to assess breast density accurately while ensuring optimal mammogram quality. Operations are streamlined for compliance and accreditation purposes, thus establishing Volpara as an indispensable partner to leading healthcare facilities on a global scale.
Frequently Asked Questions
1. What milestone did Volpara Health recently achieve?
Volpara Health recently published its 300th peer-reviewed scientific paper, showcasing its advancements in AI for breast cancer detection.
2. Why is peer-reviewed validation critical in AI mammography?
Peer-reviewed validation is vital as it provides evidence of efficacy and enhances clinical adoption of AI technologies in mammography.
3. How many facilities use Volpara Health's software?
Volpara Health's software is utilized in over 3,500 facilities worldwide, impacting millions of patients.
4. What are the benefits of Volpara's recent studies?
Recent studies highlight improved accuracy in cancer detection and better identification of women at higher risk through tailored mammogram ordering.
5. What is Volpara's overarching mission?
Volpara's mission is to save families from cancer by offering AI-powered software that facilitates personalized cancer risk assessments and screenings.
